Validation and evaluation of a common biomarker in human cancers sera protein detected by a monoclonal antibody UNIVmAb

• Main Authors: D. Manjunath, Sunil B. Kumaraswamy, Shashidhar Aladhi Venkatakrishniah, Hitesh Nidumanda Appaiah, Anil Thomas, Shib D. Banerjee
• Format: Article
• Language: English
• Published: BMC 2019-11-01
• Series: BMC Research Notes
• Subjects: ELISA; Western blot; Hyaluronic acid binding protein; H11 (sera antigen); UNIVmAb common biomarker; Cancers sera
• Online Access: http://link.springer.com/article/10.1186/s13104-019-4780-4

Abstract Objective Management and diagnosis of multiple human cancers remains a challenge and search for a common biomarker is still debatable. In this manuscript we have evaluated the use of monoclonal antibody UNIVmAb, to detect the protein (H11) as a common biomarker for all cancers irrespective of the grade and origin. We have shown by both ELISA and Western Blot that the H11 protein, is a unique hyaluronan binding protein that has not been detected earlier. H11 protein was fractionated in an anion exchange column followed by cibacron blue gel exclusion chromatography. Hyaluronan binding H11 protein reacted with Monoclonal antibody UNIVmAb and b-HA inspite of b-Hyaluronan (biotinylated Hyaluronan) interaction and HA-Oligo (Hyaluronan oligosaccharides) competition from various grades of Human cancers sera. Results ELISA, Western blot and b-Hyaluronan interactions clearly showed an over-expression of UNIVmAb reacted H11 protein in all fifty cancer’s sera when compared with seventy normal sera. UNIVmAb reactive H11 protein can be used as a common biomarker. We believe, UNIVmAb detected H11 protein, is a unique hyaluronan binding protein, that can be used as a common biomarker for all cancers.